Abstract-Diadenosine polyphosphates have been characterized as extracellular mediators controlling numerous physiological effects. In this study, diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate were isolated and identified in human myocardial tissue. Human myocardial tissue was homogenized and fractionated by affinity chromatography, displacement chromatography, anion-exchange chromatography, and reversed-phase chromatography. In fractions purified to homogeneity, diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate were revealed by matrix-assisted laser desorption/ionization mass spectrometry and ultraviolet spectroscopy. These diadenosine polyphosphates were further identified by enzymatic analysis, which demonstrated an interconnection of the phosphate groups with the adenosines in the 5Ј positions of the riboses. Furthermore, diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate were found in human cardiac-specific granules, and the amount of diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate was estimated in the range of Ϸ500 mol/L. In conclusion, the experiments show that the diadenosine polyphosphates with 2 and 3 phosphate groups occur in human myocardial tissue, and so do the diadenosine polyphosphates with 4 to 6 phosphate groups. After being released by cholinergic stimulation, which is known to affect diadenosine polyphosphate release from secretory granules, diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate activate P2X purinoceptors in vascular smooth muscle; hence, they can act as vasoconstrictors. It may be inferred that the differential action of both predominantly vasodilator and vasoconstrictor diadenosine polyphosphates allow a fine-tuning of myocardial blood flow by locally released diadenosine polyphosphates. [1] [2] [3] [4] [5] The actions of the Ap n A within the cardiovascular system are mediated by the various purinoceptor subtypes. So far, 14 mammalian purinoceptor subtypes have been cloned, 6,7 and 6 Ap n As containing 2 to 7 phosphate groups have been identified in humans. 8 -11 The affinities of a given Ap n A to the various purinoceptor subtypes depends on the number of phosphate groups linking both adenosine moieties. 9, 12, 13 Moreover, the purinoceptor subtypes are very differently distributed within the cardiovascular system. Depending on the purinoceptor subtypes activated in a given tissue, the Ap n A are both vasoconstrictors and vasodilators, 14,15 inhibitors and stimulators of platelet aggregation, 8, 9, 11 and modulators of cell proliferation. 9, 11, 16 Given this diversity of Ap n A actions, it is not surprising that the Ap n A actions reported in literature widely differ among various species. Currently, it is difficult to decide to what extent species-dependent differences in Ap n A actions are caused by different purinoceptor distribution and to species-specificity of some of the known purinoceptor subtypes.
D
iadenosine polyphosphates (Ap n A) have attracted growing interest in the past decade with respect to their roles in cardiovascular physiology and pathology. [1] [2] [3] [4] [5] The actions of the Ap n A within the cardiovascular system are mediated by the various purinoceptor subtypes. So far, 14 mammalian purinoceptor subtypes have been cloned, 6,7 and 6 Ap n As containing 2 to 7 phosphate groups have been identified in humans. 8 -11 The affinities of a given Ap n A to the various purinoceptor subtypes depends on the number of phosphate groups linking both adenosine moieties. 9, 12, 13 Moreover, the purinoceptor subtypes are very differently distributed within the cardiovascular system. Depending on the purinoceptor subtypes activated in a given tissue, the Ap n A are both vasoconstrictors and vasodilators, 14, 15 inhibitors and stimulators of platelet aggregation, 8, 9, 11 and modulators of cell proliferation. 9, 11, 16 Given this diversity of Ap n A actions, it is not surprising that the Ap n A actions reported in literature widely differ among various species. Currently, it is difficult to decide to what extent species-dependent differences in Ap n A actions are caused by different purinoceptor distribution and to species-specificity of some of the known purinoceptor subtypes.
Obviously, local concentrations of Ap n A are important determinants of Ap n A-mediated effects. 8, 9 Hence, the local production of Ap n A in the cardiovascular system has been studied recently. In earlier experiments, both Ap 2 A and Ap 3 A have been identified in human myocardial tissue. 17 Both Ap 2 A and Ap 3 A have been characterized as vasodilators, 14 whereas Ap 4 A, Ap 5 A, and Ap 6 A also have vasoconstricting properties, 10, 14 which increase with increasing number of phosphate groups. 15 Therefore, it was of interest whether Ap n A with Ͼ3 phosphate groups also occur in human myocardium. Given powerful local effects of these Ap n A, because of high local concentrations, the presence of vasoconstrictive Ap n A in human myocardium might have important consequences with respect to pathologic conditions such as myocardial infarction or excess sympathetic nerve stimulation, which is known to stimulate Ap n A release from chromaffin granules. Therefore, in the present study, we examined whether Ap n A are also present in human myocardium, which activate P2X purinoceptors in low concentrations and hence are powerful vasoconstrictors, ie, Ap n A containing 4 to 6 phosphate groups. From earlier findings in the literature, this hypothesis appeared likely, because in chromaffin granules isolated from various tissues, several or all known types of Ap n A occur. 18 -20 The experiments revealed that the Ap n A acting predominantly as vasoconstrictors are also detectable in human myocardium.
Methods

Purification Procedures
Diadenosine polyphosphates were extracted from human myocardial tissue as described previously. 17 The extract was concentrated by preparative reversed-phase chromatography (Lichroprep RP-18; 310ϫ25 mm; Merck, Germany). The eluate of the preparative reversed-phase chromatography was fractionated by size-exclusion gel, preparative anion-exchange chromatography, preparative affinity chromatography, and reversed-phase chromatography. The chromatographic conditions were identical to the methods described previously; 17 these conditions are also available in an online supplement at www.hyper.ahajournals.org.
Next, the desalted and lyophilized eluate of the affinity chromatography was dissolved in 40 mmol/L TEAA solution and was chromatographed by 2 connected reversed-phase columns (Supersphere 100 RP-18 end-capped; 300ϫ8 mm; Merck) in the displacement mode. 21 These reversed-phase columns were equilibrated with 40 mmol/L TEAA. The carrier (40 mmol/L TEAA) was pumped through the system at a flow rate of 100 L/min during injection of the sample. After the injection, n-butanol (100 mmol/L in 40 mmol/L TEAA) was used as displacer (flow rate 100 L/min). Each fraction (1 mL) was lyophilized and was further fractionated by anionexchange chromatography.
The eluate of the displacement chromatography was fractionated by analytical anion-exchange chromatography (TSK DEAE-5PW; 75ϫ7.5 mm; TosoHaas, Germany) and desalted by analytical reversed-phase chromatography (Supersphere 100 RP-18 endcapped; 100ϫ2.1 mm, 4 m; Merck). 17 The lyophilized eluate of analytical reversed-phase chromatography was analyzed by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry and postsource decay MALDI mass spectrometry using the conditions as described in Jankowski et al, 22 UV spectroscopy, 17 and enzymatic cleavage experiments. 23 
Identification of Ap n A From Human Cardiac-Specific Granules
Diadenosine polyphosphates were isolated from specific granules of human left ventricular tissue according to the method of Luo et al. 17 
Results
The extracts of human myocardial tissues were fractionated by size exclusion chromatography, anion-exchange chromatography, affinity chromatography, displacement chromatography, and analytic anion-exchange chromatography. Each fraction showing a significant UV absorption at 254 nm in the analytic anion-exchange chromatography was further chromatographed by reversed-phase chromatography. Each fraction with a significant absorbance at 254 nm of the reversedphase high-performance liquid chromatography (HPLC) was further analyzed by mass spectrometric methods, UV spectroscopy, and enzymatic analysis. ϩ , which correspond to Ap 4 A, Ap 5 A, and Ap 6 A. The UV spectra of these substances were characteristic of adenosine, with a maximum at 259 nm and minimum at 230 nm (data not shown). Moreover, the fragmentation patterns of the isolated substances were analyzed by postsource decay (PSD)-MALDI mass spectrometry. 22, 24 The results show that the analyzed substances contained phosphate groups, adenosine, AMP, ADP, ATP, Ap 4 , or Ap 5 (Table) . The fragment patterns of the analyzed fractions were identical to those of authentic Ap 4 A, Ap 5 A, and Ap 6 A (Table) . Furthermore, the interconnection of phosphate groups to the adenosines was analyzed by enzymatic analysis using alkaline phosphatase, 3Ј-nucleotide, and 5Ј-nucleotide hydrolase. Alkaline phosphatase and 3Ј-nucleotidase had no effect on these molecules (data not shown). The 5Ј-nucleotidase yielded AMP and ATP (Figure 2A ) after incubation of the fraction labeled in Figure 1A , AMP and Ap 4 ( Figure 2B ) after incubation of the fraction labeled in Figure  1B , and AMP and Ap 5 ( Figure 2C ) after incubation of the fraction labeled in Figure 1C . The retention time in cleavage patterns is in accord with those of authentic Ap 4 A, Ap 5 A, and Ap 6 A. These results demonstrate that all adenosines in the purified molecules are interconnected via 5Ј-phosphodiester bonds of the riboses with the phosphates. In summary, by MALDI mass spectrometry, UV absorption analysis, PSD-MALDI mass spectrometry, and enzymatic analysis, the substances underlying the UV absorption peaks in the reversed-phase HPLC shown in Figure 1 
Discussion
Whereas in earlier studies only Ap 2 A and Ap 3 A had been isolated from human myocardium, 17 the present study shows that Ap n A containing 4 to 6 phosphate moieties are also found in human myocardial tissue. Moreover, Ap 4 A, Ap 5 A, and Ap 6 A were identified in myocardial-specific granules, which are known to release their contents into the extracellular space after stimulation, eg, by cholinergic agonists. 18, 25 The concentrations of Ap 4 A, Ap 5 A, and Ap 6 A (see Results) in specific granules are not very different from those of Ap 2 A and Ap 3 A found earlier. 17 Why had Ap 4 A, Ap 5 A, and Ap 6 A not been identified in our previous study? 17 Most likely, methodological reasons may be responsible. The purification procedure in this study has been considerably improved with respect to the recovery of Ap n A compared with the previous study. In this study, but not in the previous one, we used displacement chromatography before the analytic anionexchange chromatography and reversed-phase HPLC. This procedure may be more effective to separate Ap n A from myocardial tissue, because displacement chromatography has been shown to be a powerful method for separation of dinucleotide polyphosphates. 26 From the presence of at least 5 different Ap n As in human myocardial tissue, it can be inferred that Ap n A may have specific functions in human heart. What is the significance of these findings for cardiac physiology and pathology? To 
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answer this question, the cardiovascular effects of Ap n A have to be considered. Although presently our knowledge of the role of these molecules is still quite incomplete, animal experiments have given some hints as to potential physiological functions of these molecules. 33 Furthermore, Ap 4 A, Ap 5 A, and Ap 6 A are potent inhibitors of myocardial K ATP channels. 34 -37 The concentration of Ap 4 A in coronary venous blood is increased during ischemia and reperfusion of heart, whereas it cannot be detected with normal oxygen supply. 35 This increase of Ap 4 A during ischemia is probably caused by the release of Ap 4 A stored in myocardial-specific granules and activated platelets in blood. 38 Ap 4 A reduces cardiac infarct size and reperfusion injury in the ischemic canine heart. Furthermore, Ap 4 A mimics cardioprotective effect of ischemic preconditioning in the rat heart and significantly improves the postischemic recovery of cardiac function, reducing the leakage of serum creatine kinase. 39 Ap 4 A has cardioprotective effects on hypothermic heart storage and cardioplegia. 40, 41 Some of these effects of Ap 4 A appear to be mediated by activating protein kinase C and mitochondrial K ATP channels via P2 years mimicking, in part, the effects of ischemic preconditioning. 42 Moreover, Ap 4 A is an intracellular regulator ligand of the sarcolemmal K ATP channel. 42, 43 Therefore, the intracellular Ap 4 A may directly interact with the mitochondrial K ATP channel or is released to extracellular spaces and interacts with adjacent cells.
Ap 5 A was shown to bind to the nucleotide-binding domain of the myocardial K ATP channel, 43 thus decreasing channel opening probability. The ischemia-induced decreased Ap 5 A levels may thus contribute to open the K ATP channel under ischemic conditions. The K ATP channel is known to be a sensor of metabolic stress, especially of cellular hypoxia: With decreasing ATP concentrations, the opening probability of this channel increases. This may be an important mechanism for cells undergoing hypoxia to maintain membrane potential despite decreased function of transmembrane ion pumps such as the energy-dependent Na-K-ATPase.
The regulation of K ATP channels appears to be only a small segment of the potential regulatory functions of myocardial Ap n A. It may be assumed that Ap 5 A may have further effects on myocardial ion channels and purinoceptors, and so may the other Ap n As show regulatory effects, although differing according to the number of phosphate moieties. Taken together with the present findings, it may be inferred that the Ap n A represent a new class of messengers in human myocardial cells, exhibiting cellular protective functions in metabolic or ischemic stress. Also, there are other still unknown effects that are dependent on their binding to purinoceptors and ion channels.
Perspectives
Given that the research on myocardial Ap n A is at its very beginning, it is likely that changes in the patterns of Ap n A levels associated with different metabolic or vascular disorders may have further still unknown effects in the pathophysiology of heart disease.
